NTP-RISEDRONATE TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
26-07-2012
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE)
Tilgjengelig fra:
NT PHARMA CANADA LTD
ATC-kode:
M05BA07
INN (International Name):
RISEDRONIC ACID
Dosering :
30MG
Legemiddelform:
TABLET
Sammensetning:
RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 30MG
Administreringsrute:
ORAL
Enheter i pakken:
30
Resept typen:
Prescription
Terapeutisk område:
BONE RESORPTION INHIBITORS
Produkt oppsummering:
Active ingredient group (AIG) number: 0135301001; AHFS:
Autorisasjon status:
CANCELLED PRE MARKET
Autorisasjon dato:
2017-03-16
Preparatomtale
PRODUCT MONOGRAPH
PR
NTP-RISEDRONATE
Risedronate sodium (as the monohydrate)
5 mg, 30 mg and 35 mg Tablets
Bone Metabolism Regulator
NT Pharma Canada Ltd.
5691 Main Street
Stouffville, Ontario
Canada, L4A 1H5
Submission Control No: 156479
Date of Revision:
July 26, 2012
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................
11
DOSAGE AND ADMINISTRATION
.....................................................................................
13
OVERDOSAGE
.......................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 15
STORAGE AND STABILITY
.................................................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 19
PART II: SCIENTIFIC INFORMATION
...............................................................................
21
PHARMACEUTICAL INFORMATION
.................................................................................
21
CLINICAL TRIALS
.................................................................................................................
22
Les hele dokumentet
